Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model
The Department of Health and Department of Corrections will now establish a contract with Asegua Therapeutics to make its medication, the authorized generic of Epclusa® (sofosbuvir/velpatasvir tablets), available to hepatitis C patients enrolled in Medicaid and to treat incarcerated patients over the next five years.